Video

ARVO LIVE: lysyl oxidase and stiffening blood vessels in the eye

Ophthalmology Times® talked with Kaustubh Ghosh, PhD, about lysyl oxidase, a recently discovered molecule that causes the blood vessels in the eye to become stiffer at this year's ARVO meeting.

Ophthalmology Times® talked with Kaustubh Ghosh, PhD, about lysyl oxidase, a recently discovered molecule that causes the blood vessels in the eye to become stiffer at this year's ARVO meeting.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Kaustubh Ghosh, PhD:

My name is Kaustubh Ghosh. I'm an associate professor of ophthalmology at UCLA and a principal investigator at the Doheny Eye Institute. And, the work that we presented at this ARVO, it focuses on this one particular molecule called lysyl oxidase that we recently discovered, causes the blood vessels in the eye to become stiffer. In other words, normal retinal blood vessels that feel like a plastic straw, become stiffer and feel like a hard plumbing pipe.

And this change in the stiffness of the blood vessels in the eye, causes them to degenerate very quickly. So, we found the mechanism meaning the molecular mechanism that causes the blood vessels to become stiffer. Our studies in mice show that if we block this particular molecule, the blood vessels do not become stiffer, and by preventing the stiffening, we can also rescue these blood vessels from degeneration that is characteristic of diabetes and aging.

We're now trying to identify therapeutic drugs that can block this vascular stiffening and the subsequent mechanical biological processes that result from this increase in stiffness so that we can develop new therapies for clinical management, more effective clinical management of diabetic retinopathy and age-related macular degeneration.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.